Skip to content

Damora Therapeutics

US · DMRA #3109 by market cap Listed 1970
23.22 -1.08 -4.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Cuts Target Price to $59
    Market Newswire · 2026/11/6
  • Rating change
    Leerink Partners Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $51
    Market Newswire · 2026/5/15
  • Rating change
    Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/9/25
  • Rating change
    Evercore Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $46
    Market Newswire · 2026/3/25
  • Rating change
    Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/7/30
  • Rating change
    Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/6/16
  • Rating change
    Jefferies Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $50
    Market Newswire · 2026/7/27
  • Rating change
    TD Cowen Initiates Damora Therapeutics(DMRA.US) With Buy Rating
    Market Newswire · 2026/6/8
  • Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/11/6
  • Rating change
    LifeSci Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/9/19
  • RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/11/5
  • Rating change
    H.C. Wainwright Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $45
    Market Newswire · 2026/6/11
  • Rating change
    RBC Capital Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $40
    Market Newswire · 2026/4/24
  • Leerink Partners Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $51
    Market Newswire · 2026/11/5
  • Rating change
    A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $45
    Market Newswire · 2026/8/11
  • Rating change
    A Quick Look at Today's Ratings for Damora Therapeutics(DMRA.US), With a Forecast Between $40 to $50
    Market Newswire · 2026/8/12
  • H.C. Wainwright Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/11/5
  • Rating change
    Wedbush Initiates Damora Therapeutics(DMRA.US) With Buy Rating, Announces Target Price $35
    Market Newswire · 2026/5/28
  • Rating change
    TD Cowen Maintains Damora Therapeutics(DMRA.US) With Buy Rating
    Market Newswire · 2026/6/12
  • Rating change
    Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/6/15
  • Rating change
    RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/6/30
  • Wedbush Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/9/29
  • Rating change
    H.C. Wainwright Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $45
    Market Newswire · 2026/8/6

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Damora Therapeutics discussion 0 comments

Add a comment